B and T Lymphocyte Attenuator Is Highly Expressed on CMV-Specific T Cells during Infection and Regulates Their Function
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
B and T lymphocyte attenuator (BTLA), like its relative programmed cell death-1 (PD-1), is a receptor that negatively regulates murine T cell activation. However, its expression and function on human T cells is currently unknown. We report in this study on the expression of BTLA in human T cell subsets as well as its regulation on virus-specific T cells during primary human CMV infection. BTLA is expressed on human CD4+ T cells during different stages of differentiation, whereas on CD8+ T cells, it is found on naive T cells and is progressively downregulated in memory and differentiated effector-type cells. During primary CMV infection, BTLA was highly induced on CMV-specific CD8+ T cells immediately following their differentiation from naive cells. After control of CMV infection, BTLA expression went down on memory CD8+ cells. Engagement of BTLA by mAbs blocked CD3/CD28-mediated T cell proliferation and Th1 and Th2 cytokine secretion. Finally, in vitro blockade of the BTLA pathway augmented, as efficient as anti–PD-1 mAbs, allogeneic as well as CMV-specific CD8+ T cell proliferation. Thus, our results suggest that, like PD-1, BTLA provides a potential target for enhancing the functional capacity of CTLs in viral infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“and a recently identified molecule known as B and T lymphocyte attenuator (BTLA) (1, 2).”
BackgroundBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246 · cited 1×
“anti-human PD-1 and anti-human BTLA mAbs (26, 29).”
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Petrovas, C., Casazza, J. P., Brenchley, J. M., Price, D. A., Gostick, E., Adams, W. C., Precopio, M. L., Schacker, T., Roederer, M., Douek, D. C., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061496 · Cited by 889 · cited 1×
“of PD-1 was proposed to be a likely mechanism for the control of proliferation and apoptosis of activated cells (6).”
BackgroundBTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · cited 7×
“First, BTLA was initially identified as having inhibitory actions on T cell proliferation and cytokine production in vitro (11, 12).”
BackgroundInfluentialPhenotype and function of human T lymphocyte subsets: Consensus and issues
Appay, V., van Lier, R. A. W., Sallusto, F., & Roederer, M. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20643 · Cited by 729
Human CD8+ T-cell differentiation in response to viruses
van Lier, R. A. W., ten Berge, I. J. M., & Gamadia, L. E. (2003) · Nature Reviews Immunology · doi:10.1038/nri1254 · Cited by 297
Cited by
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Self-citationPD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365
Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases
Serriari, N.-E., Eoche, M., Lamotte, L., Lion, J., Fumery, M., Marcelo, P., Chatelain, D., Barre, A., Nguyen-Khac, E., Lantz, O., et al. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12277 · Cited by 334
Self-citationGoronzy, J. J., & Weyand, C. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0970-0 · Cited by 292
“Negative regulatory receptors characteristic of clonal exhaustion, such as PD-1 and BTLA, are not expressed [56].”
BackgroundRoles of BTLA in Immunity and Immune Disorders
Ning, Z., Liu, K., & Xiong, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654960 · Cited by 157
“During infection with primary cytomegalovirus (CMV), BTLA is highly induced in CD8+ T cells, and BTLA blockade enhances CMV-specific CD8+ T cell proliferation (92).”
BackgroundInfluentialTumor Necrosis Factor Superfamily in Innate Immunity and Inflammation
Šedý, J., Bekiaris, V., & Ware, C. F. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016279 · Cited by 109
Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling
Shui, J.-W., Steinberg, M. W., & Kronenberg, M. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0910528 · Cited by 109
BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection
Yu, X., Zheng, Y., Mao, R., Su, Z., & Zhang, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00617 · Cited by 83
“Research has demonstrated that the HBVM-BTLA signaling pathway plays an important role in cancer (14, 61), intestinal inflammation (12), autoimmune diseases (4, 13), viral infection (62), transplant rejection (11, 63), and in continuous chronic HBV infection.”
BackgroundYang, C., Chen, Y., Guo, G., Li, H., Cao, D., Xu, H., Guo, S., Fei, L., Yan, W., Ning, Q., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302239 · Cited by 41
Wang, H., Wu, B., Li, L., Hu, L., Lin, J., Jiang, C., Cai, G., & Shen, Q. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2016.10.002 · Cited by 32
Cai, G., Nie, X., Li, L., Hu, L., Wu, B., Lin, J., Jiang, C., Wang, H., Wang, X., & Shen, Q. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0762-9 · Cited by 27
“In bone marrow transplant patients with CMV infection, BTLA was not upregulated on CD4 T cells, but increased on CMV specific CTLs during viremia [18].”
BackgroundResultXu, H., Cao, D., Guo, G., Ruan, Z., Wu, Y., & Chen, Y. (2012) · Diagnostic Pathology · doi:10.1186/1746-1596-7-142 · Cited by 27
Metadata
- Authors
- Serriari, N.-E., Gondois-Rey, F., Guillaume, Y., Remmerswaal, E. B. M., Pastor, S., Messal, N., Truneh, A., Hirsch, I., van Lier, R. A. W., & Olive, D.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09
- Volume
- 185
- Issue
- 6
- Pages
- 3140-3148
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2142297811
- Cited by
- 70
- References
- 11
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.